You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Breast Cancer, HER2 Negative, Hormone receptor positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

    Active, not recruiting
    • Hormone-receptor-positive Breast Cancer
    • +2 more
    • No drug
    • Cambridge, Massachusetts
      ConcertAI database
    Sep 8, 2023

    Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

    Not yet recruiting
    • Locoregional Recurrence
    • +2 more
    • (no location specified)
    Jul 18, 2022

    Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

    Recruiting
    • Locally Advanced or Unresectable Metastatic Breast Cancer
    • Stage IV Breast Cancer
    • Sacituzumab Govitecan-hziy
    • +3 more
    • Marietta, Georgia
    • +1 more
    Apr 21, 2023

    HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

    Recruiting
    • HR+/HER2- Advanced Breast Cancer
    • Targeted Therapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Aug 1, 2023

    Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

    Not yet recruiting
    • Breast Cancer Invasive
    • +3 more
    • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Nov 17, 2023

    Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

    Recruiting
    • Breast Cancer
    • Saint Louis, Missouri
    • +2 more
    Jan 12, 2023

    Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Aug 4, 2023

    Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)

    Active, not recruiting
    • Breast Cancer
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Dec 13, 2022

    HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

    Not yet recruiting
    • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
    • PERT-IJS plus trastuzumab, carboplatin and docetaxel
    • Perjeta plus trastuzumab, carboplatin and docetaxel
    • (no location specified)
    Sep 21, 2023

    Real-World Data on First-line Treatment of Hormone

    Recruiting
    • Breast Cancer
      • Porto Alegre, Rio Grande Do Sul, Brazil
        CPO
      Aug 15, 2022

      Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

      Not yet recruiting
      • Anatomic Stage I Breast Cancer AJCC v8
      • +5 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Jul 14, 2022

      Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Stanford, California
        Stanford University
      Nov 16, 2022

      Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

      Active, not recruiting
      • Metastatic Breast Cancer
      • Hospitalet de Llobregat, Barcelona, Spain
      • +6 more
      Jan 23, 2023

      Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

      Recruiting
      • Metastatic Breast Cancer
      • +2 more
      • Ocala, Florida
        Ocala Oncology Center PL DBA Florida Cancer Affiliates
      Jul 19, 2023

      Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)

      Not yet recruiting
      • Advanced or Metastatic Breast Cancer
      • (no location specified)
      Oct 24, 2023

      Breast Cancer Stage II Trial in Xi'an (Anlotinib)

      Recruiting
      • Breast Cancer Stage II
      • Xi'an, Shannxi Province, China
        Xijing Hospital Affiliated to Air Force Military Medical Univers
      Sep 25, 2022

      Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

      Not yet recruiting
      • Hormone Receptor-positive Breast Cancer
      • +2 more
      • Nashville, Tennessee
        Sarah Cannon Research Institute
      Oct 5, 2022

      Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in

      Withdrawn
      • Anatomic Stage IV Breast Cancer AJCC v8
      • +4 more
      • Bintrafusp Alfa
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 2, 2022